EGenesis is at the forefront of addressing the critical shortage of transplantable organs through innovative approaches in xenotransplantation. The company is focused on developing Human Compatible (HuCo™) organs and cells, which aim to bridge the gap between the growing demand for transplants and the limited supply of human donor organs. By leveraging advanced gene editing technologies through their EGenesis Genome Engineering and Production (EGEN™) Platform, EGenesis is tackling the historical challenges associated with xenotransplantation, particularly in the development of organs such as kidneys and islet cells. This transformative research is driven by the vision of a future where the availability of transplantable organs does not dictate the quality of life for patients in need.

EGenesis has a robust pipeline of programs aimed at addressing urgent medical needs related to organ failure and other debilitating diseases. Their research spans various stages, including preclinical and clinical development, with a focus on solid organs and cell therapies. The company is actively working on several initiatives, including HuCo™ liver, kidney, and heart perfusion, which are designed to enhance the viability and compatibility of transplanted organs. Through these efforts, EGenesis is committed to improving patient outcomes and alleviating the suffering associated with the current transplant shortage crisis.

United States

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. 

EGenesis

Company Details